Wiltshire-based Vectura Group, an industry leading inhalation products company, has signed a global out licence and development agreement with US company Kinaset Therapeutics Inc.

The deal is for the development and commercialisation a preclinical novel inhaled pan-JAK inhibitor for the prevention and treatment of severe asthma.

Pan-JAK inhibitors have been developed and tested in clinical trials, approved and commercialised for many different indications but mainly for the treatment of chronic inflammatory conditions associated with an overactive immune response.